TR200002930T2 - Facilitating compositions - Google Patents

Facilitating compositions

Info

Publication number
TR200002930T2
TR200002930T2 TR2000/02930T TR200002930T TR200002930T2 TR 200002930 T2 TR200002930 T2 TR 200002930T2 TR 2000/02930 T TR2000/02930 T TR 2000/02930T TR 200002930 T TR200002930 T TR 200002930T TR 200002930 T2 TR200002930 T2 TR 200002930T2
Authority
TR
Turkey
Prior art keywords
adjuvant
facilitating
polyoxyethylene
relates
present
Prior art date
Application number
TR2000/02930T
Other languages
Turkish (tr)
Inventor
Friede Martin
Hermand Philippe
Original Assignee
Smithkline Beecham Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9807805.8A external-priority patent/GB9807805D0/en
Priority claimed from GBGB9820956.2A external-priority patent/GB9820956D0/en
Application filed by Smithkline Beecham Biologicals S.A. filed Critical Smithkline Beecham Biologicals S.A.
Publication of TR200002930T2 publication Critical patent/TR200002930T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mevcut bulus, farmasötik açidan kabul edilebilir bir kolaylastirici ile birlikte bir polioksietilen eterini veya bir polioksietilen esterini içeren bir kolaylastirici ve bu kolaylastirici kompozisyonlarini ve antijen içeren bir asi ile ilgilidir. Ek olarak mevcut bulus, polioksietilen eterlerinin veya esterlerinin, kolaylastirici formülasyonlarinin ve asi formülasyonlarinin üretiminde kullanilmasi ve bunlarin ilaç olarak kullanilmalari ile ilgilidir.The present invention relates to an adjuvant comprising a polyoxyethylene ether or a polyoxyethylene ester together with a pharmaceutically acceptable adjuvant and an adjuvant containing these adjuvant compositions and antigen. In addition, the present invention relates to the use of polyoxyethylene ethers or esters, facilitating formulations and vaccine formulations, and their use as medicines.

TR2000/02930T 1998-04-09 1999-03-29 Facilitating compositions TR200002930T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9807805.8A GB9807805D0 (en) 1998-04-09 1998-04-09 Vaccine
GBGB9820956.2A GB9820956D0 (en) 1998-09-25 1998-09-25 Vaccine

Publications (1)

Publication Number Publication Date
TR200002930T2 true TR200002930T2 (en) 2000-12-21

Family

ID=26313462

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02930T TR200002930T2 (en) 1998-04-09 1999-03-29 Facilitating compositions

Country Status (15)

Country Link
EP (1) EP1069910A1 (en)
JP (1) JP2002511423A (en)
KR (1) KR20010042573A (en)
CN (1) CN1296416A (en)
AR (1) AR019026A1 (en)
AU (1) AU746163B2 (en)
BR (1) BR9909915A (en)
CA (1) CA2325939A1 (en)
HU (1) HUP0101619A3 (en)
IL (1) IL138000A0 (en)
NO (1) NO20005051L (en)
NZ (1) NZ506603A (en)
PL (1) PL354714A1 (en)
TR (1) TR200002930T2 (en)
WO (1) WO1999052549A1 (en)

Families Citing this family (230)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1997025429A1 (en) 1996-01-04 1997-07-17 Rican Limited Helicobacter pylori bacterioferritin
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO1999061056A2 (en) 1998-05-22 1999-12-02 Loeb Health Research Institute At The Ottawa Hospital Methods and products for inducing mucosal immunity
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
BR0014285A (en) * 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvants comprising a polyoxyethylene alkyl ester or ether and at least one nonionic surfactant
WO2001021151A1 (en) * 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Intranasal influenza virus vaccine
CA2396871A1 (en) * 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
NZ520673A (en) 2000-02-23 2004-09-24 Smithkline Beecham Biolog S Tumour-specific animal proteins
CN1606446A (en) 2000-05-19 2005-04-13 科里克萨有限公司 Method for preventing and treating communicable diseases and other diseases using monosaccharides and disaccharides
JP5139618B2 (en) 2000-06-20 2013-02-06 コリクサ コーポレイション Mycobacterium tuberculosis fusion protein
WO2002000174A2 (en) 2000-06-28 2002-01-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AR030829A1 (en) * 2000-10-02 2003-09-03 Smithkline Beecham Biolog A FORMATION OF VACCINE, PROCEDURE FOR THE PRODUCTION OF THE SAME, USE OF SUCH PREPARATION AND A CASE FOR ADMINISTRATION VIA INTRANASAL
NZ540544A (en) 2000-10-27 2007-08-31 Inst Genomic Research Nucleic acids and proteins from streptococcus groups A & B
EP2336368A1 (en) 2000-12-07 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
JP2004527524A (en) * 2001-04-05 2004-09-09 カイロン コーポレイション Mucosal boost after parenteral priming
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
RU2316347C2 (en) 2001-06-29 2008-02-10 Чирон Корпорейшн Composition for immune response stimulation (variants), methods for production and using thereof and method for immune response stimulation using the same
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
AU2002365279B2 (en) 2001-12-17 2009-08-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
JP4646516B2 (en) 2002-02-20 2011-03-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Fine particles with adsorbed polypeptide-containing molecules
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
SE0201701D0 (en) * 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections
AU2003276679A1 (en) 2002-06-13 2003-12-31 Chiron Corporation Vectors for expression of hml-2 polypeptides
EP1387167B1 (en) * 2002-07-24 2008-05-07 Centre National De La Recherche Scientifique (Cnrs) Method for identifying biologically active compounds with anti-asthmatic and/or anti-allergic properties
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US20040132652A1 (en) * 2002-08-30 2004-07-08 Shire Biochem Inc. Pharmaceutical compositions
US8663656B2 (en) 2002-10-11 2014-03-04 Novartis Ag Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
CN101948835A (en) 2002-10-29 2011-01-19 科勒制药集团股份有限公司 The application of CPG oligonucleotide in the treatment infection with hepatitis C virus
CA2506318C (en) 2002-11-15 2011-07-12 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP2263687B1 (en) 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
SI1589934T1 (en) 2003-01-06 2016-02-29 Corixa Corporation Corporation Service Company Certain aminoalkyl glucosaminide phosphate compounds and their use
JP4827726B2 (en) 2003-01-30 2011-11-30 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Injectable vaccine against multiple meningococcal serogroups
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
WO2004092360A2 (en) 2003-04-10 2004-10-28 Chiron Corporation The severe acute respiratory syndrome coronavirus
PL1631264T5 (en) 2003-06-02 2018-09-28 Glaxosmithkline Biologicals Sa Immunogenic compositions based on biodegradable microparticles comprising a diphtheria- and a tetanus toxoid
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1670506B1 (en) 2003-10-02 2012-11-21 Novartis AG Liquid vaccines for multiple meningococcal serogroups
AU2004308964B2 (en) 2003-12-23 2010-09-16 Arbor Vita Corporation Antibodies for oncogenic strains of HPV and methods of their use
WO2005107797A1 (en) 2004-03-09 2005-11-17 Chiron Corporation Influenza virus vaccines
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
AU2005237289B2 (en) 2004-04-30 2011-08-04 Glaxosmithkline Biologicals S.A. Meningococcal conjugate vaccination
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
JP4896021B2 (en) 2004-05-21 2012-03-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Alphavirus vector for respiratory pathogen vaccine
CA2567597C (en) 2004-05-25 2014-03-18 Oregon Health And Science University Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
CA2575548A1 (en) 2004-07-29 2006-07-27 John L. Telford Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
ES2616294T3 (en) 2005-01-27 2017-06-12 Children's Hospital & Research Center At Oakland GNA1870-based vesicle vaccines for broad-spectrum protection against diseases caused by Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
US8758764B2 (en) 2005-02-18 2014-06-24 Novartis Vaccines And Diagnostics Srl Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
MX291624B (en) 2005-02-18 2011-11-04 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli.
CN103372206A (en) 2005-03-31 2013-10-30 葛兰素史密丝克莱恩生物有限公司 Vaccines against chlamydial infection
CN101237881B (en) * 2005-08-03 2015-04-22 伊缪诺金公司 Immunoconjugate formulations
JP2009511636A (en) 2005-10-18 2009-03-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Mucosal and systemic immunity with alphavirus replicon particles
EP1776963A1 (en) 2005-10-19 2007-04-25 Gbf-Gesellschaft Für Biotechnologische Forschung Mbh Hexosylceramides as adjuvants and their uses in pharmaceutical compositions
JP2009514838A (en) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Adjuvant vaccine containing non-virion antigen prepared from influenza virus grown in cell culture
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP1976559B3 (en) 2006-01-27 2020-02-19 Seqirus UK Limited Influenza vaccines containing hemagglutinin and matrix proteins
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2382987A1 (en) 2006-03-24 2011-11-02 Novartis Vaccines and Diagnostics GmbH Storage of influenza vaccines without refrigeration
CA2647942A1 (en) 2006-03-31 2007-11-08 Novartis Ag Combined mucosal and parenteral immunization against hiv
EP2054431B1 (en) 2006-06-09 2011-08-31 Novartis AG Conformers of bacterial adhesins
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2064230A2 (en) 2006-08-16 2009-06-03 Novartis AG Immunogens from uropathogenic escherichia coli
EP1897557A1 (en) * 2006-09-07 2008-03-12 Helmholtz-Zentrum für Infektionsforschung GmbH Use of glycolipids as adjuvants
EP3456348A1 (en) 2006-09-11 2019-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
WO2008068631A2 (en) 2006-12-06 2008-06-12 Novartis Ag Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
MX351247B (en) 2007-04-04 2017-10-05 Infectious Disease Res Institute Star Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof.
KR20100045437A (en) 2007-06-27 2010-05-03 노파르티스 아게 Low-additive influenza vaccines
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CN101795709B (en) 2007-08-02 2013-07-17 彼昂德瓦克斯医药有限公司 Multimeric multiepitope influenza vaccines
WO2009020553A2 (en) 2007-08-03 2009-02-12 President And Fellows Of Harvard College Chlamydia antigens
KR101621837B1 (en) 2007-09-12 2016-05-17 노파르티스 아게 Gas57 mutant antigens and gas57 antibodies
US8236318B2 (en) 2007-11-07 2012-08-07 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
CA2744739A1 (en) 2007-12-03 2009-06-11 President And Fellows Of Harvard College Chlamydia antigens
ES2664753T3 (en) 2007-12-07 2018-04-23 Glaxosmithkline Biologicals Sa Immune response induction compositions
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
PL2235046T3 (en) 2007-12-21 2012-12-31 Novartis Ag Mutant forms of streptolysin o
ES2532946T3 (en) 2008-02-21 2015-04-06 Novartis Ag Meningococcal PUfH polypeptides
ES2557282T3 (en) 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Chimeric H-factor binding proteins (fHBP) containing a heterologous B domain, and methods of use
CN102239253A (en) 2008-12-03 2011-11-09 普罗蒂亚维仕尼科技有限公司 Glutamyl trna synthetase (GTS) fragments
BRPI0922561A2 (en) 2008-12-09 2020-08-11 Pfizer Vaccines Llc ige ch3 peptide vaccine.
AU2010204139A1 (en) 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
RU2011140508A (en) 2009-03-06 2013-04-20 Новартис Аг Chlamydia antigens
US8679505B2 (en) 2009-04-14 2014-03-25 Novartis Ag Compositions for immunising against Staphylococcus aureus
KR101450958B1 (en) 2009-04-30 2014-10-15 콜레이 파마시티컬 그룹, 인코포레이티드 Pneumococcal vaccine and uses therof
EP2442826B1 (en) 2009-06-15 2015-07-08 National University of Singapore Influenza vaccine, composition, and methods of use
US10988511B2 (en) 2009-07-07 2021-04-27 Glaxosmithkline Biologicals Sa Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens
HUE058971T2 (en) 2009-07-15 2022-09-28 Glaxosmithkline Biologicals Sa Rsv f protein compositions and methods for making same
SG178035A1 (en) 2009-07-16 2012-03-29 Novartis Ag Detoxified escherichia coli immunogens
PE20120817A1 (en) 2009-07-30 2012-07-07 Pfizer Vaccines Llc ANTIGENIC TAU PEPTIDES AND USES OF THEM
US20110076300A1 (en) 2009-08-27 2011-03-31 Mariagrazia Pizza Hybrid Polypeptides Including Meningococcal fHBP Sequences
PT2473605T (en) 2009-09-03 2018-05-28 Pfizer Vaccines Llc Pcsk9 vaccine
CN102596254B (en) 2009-09-30 2016-10-19 诺华股份有限公司 Staphylococcus aureus 5 type and the coupling of CP8
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
JP5960055B2 (en) 2009-10-27 2016-08-02 ノバルティス アーゲー Modified meningococcal fHBP polypeptide
WO2011056899A2 (en) 2009-11-03 2011-05-12 Ligocyte Pharmaceuticals, Inc. Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
CA2785585A1 (en) 2009-12-22 2011-06-30 Celldex Therapeutics, Inc. Vaccine compositions
ES2707778T3 (en) 2009-12-30 2019-04-05 Glaxosmithkline Biologicals Sa Immunogens polysaccharides conjugated with carrier proteins of E. coli
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
TR201802933T4 (en) 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland The modified factor h binding proteins (fhbp) and their method of use.
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011127316A1 (en) 2010-04-07 2011-10-13 Novartis Ag Method for generating a parvovirus b19 virus-like particle
EA024701B1 (en) 2010-04-13 2016-10-31 Селлдекс Терапьютикс Инк. Antibodies that bind human cd27 and uses thereof
EP2558069A1 (en) 2010-04-13 2013-02-20 Novartis AG Benzonapthyridine compositions and uses thereof
CN102933267B (en) 2010-05-28 2015-05-27 泰特里斯在线公司 Interactive hybrid asynchronous computer game infrastructure
US8895017B2 (en) 2010-06-07 2014-11-25 Pfizer Inc. HER-2 peptides and vaccines
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
EP2591097A1 (en) 2010-07-06 2013-05-15 Novartis AG Norovirus derived immunogenic compositions and methods
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012057904A1 (en) 2010-10-27 2012-05-03 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
ES2859673T3 (en) 2010-11-08 2021-10-04 Infectious Disease Res Inst Vaccines comprising nonspecific nucleoside hydrolase polypeptides and sterol 24-c-methyltransferase (SMT) for the treatment and diagnosis of leishmaniasis
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
ES2574403T3 (en) * 2010-12-14 2016-06-17 Glaxosmithkline Biologicals S.A. Antigenic composition of mycobacteria
EP2655389A2 (en) 2010-12-24 2013-10-30 Novartis AG Compounds
ES2727836T3 (en) 2011-01-26 2019-10-21 Glaxosmithkline Biologicals Sa RSV immunization regimen
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
PL3275892T3 (en) 2011-05-13 2020-09-07 Glaxosmithkline Biologicals S.A. Pre-fusion rsv f antigens
MX2013013627A (en) 2011-06-21 2014-04-25 Oncofactor Corp Compositions and methods for the therapy and diagnosis of cancer.
JP2014520807A (en) 2011-07-06 2014-08-25 ノバルティス アーゲー Immunogenic compositions and uses thereof
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
US10030052B2 (en) 2011-07-25 2018-07-24 Glaxosmithkline Biologicals Sa Parvovirus Vp1 unique region polypeptides and compositions thereof
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
JP2014531442A (en) 2011-09-14 2014-11-27 ノバルティス アーゲー Escherichia coli vaccine combination
ES2704069T3 (en) 2011-12-08 2019-03-14 Glaxosmithkline Biologicals Sa Clostridium difficile toxin-based vaccine
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
AU2013224026A1 (en) 2012-02-24 2014-08-21 Novartis Ag Pilus proteins and compositions
EP3492095A1 (en) 2012-04-01 2019-06-05 Technion Research & Development Foundation Limited Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
JP6401148B2 (en) 2012-04-26 2018-10-03 ノバルティス アーゲー Antigens and antigen combinations
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
KR102125658B1 (en) 2012-05-04 2020-06-22 화이자 인코포레이티드 Prostate-associated antigens and vaccine-based immunotherapy regimens
KR20150021933A (en) 2012-05-22 2015-03-03 노파르티스 아게 Meningococcus serogroup x conjugate
WO2014005958A1 (en) 2012-07-06 2014-01-09 Novartis Ag Immunogenic compositions and uses thereof
HUE065746T2 (en) 2012-08-03 2024-06-28 Access To Advanced Health Inst Compositions and methods for treating an active mycobacterium tuberculosis infection
CA2885625A1 (en) 2012-10-02 2014-04-10 Glaxosmithkline Biologicals S.A. Nonlinear saccharide conjugates
ES2848048T3 (en) 2012-10-03 2021-08-05 Glaxosmithkline Biologicals Sa Immunogenic compositions
ES2656510T3 (en) 2012-11-30 2018-02-27 Glaxosmithkline Biologicals S.A. Pseudomonas antigens and antigen combination
EP2978447B1 (en) 2013-03-28 2019-05-08 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
AU2014385320B2 (en) 2013-05-15 2019-10-10 The Governors Of The University Of Alberta E1E2 HCV vaccines and methods of use
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN110787290B (en) 2014-01-21 2024-06-04 辉瑞公司 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3104877B1 (en) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9 vaccine and methods of using the same
EP4074726A3 (en) 2014-07-23 2022-11-23 Children's Hospital & Research Center at Oakland Factor h binding protein variants and methods of use thereof
AR102548A1 (en) 2014-11-07 2017-03-08 Takeda Vaccines Inc VACCINES AGAINST HAND, FEET AND MOUTH DISEASE AND MANUFACTURING AND USE METHODS
MA40920A (en) 2014-11-07 2017-09-12 Takeda Vaccines Inc VACCINES OF THE HAND, FOOT AND MOUTH, AND METHODS OF MANUFACTURING AND USE THEREOF
AU2015365583B2 (en) 2014-12-19 2021-10-28 Regenesance B.V. Antibodies that bind human C6 and uses thereof
BR112017013891B1 (en) 2015-01-15 2024-01-30 Pfizer Inc IMMUNOGENIC COMPOSITIONS FOR USE IN PNEUMOCOCCAL VACCINES
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
RU2017140856A (en) 2015-05-26 2019-06-26 Огайо Стейт Инновейшн Фаундейшн STRATEGY OF VACCINATION AGAINST THE VIRUS OF SWINE FLU VACCINE ON THE BASIS OF NANOPARTICLES
US10576131B2 (en) 2015-06-03 2020-03-03 Affiris Ag IL-23-p19 vaccines
JP2018522885A (en) 2015-07-07 2018-08-16 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ Vaccines for the treatment and prevention of IgE-mediated diseases
TWI720448B (en) 2015-07-21 2021-03-01 美商輝瑞股份有限公司 Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3377098A1 (en) 2015-11-20 2018-09-26 Pfizer Inc Immunogenic compositions for use in pneumococcal vaccines
TWI709647B (en) 2016-01-19 2020-11-11 美商輝瑞股份有限公司 Cancer vaccines
US20200377606A1 (en) 2016-04-18 2020-12-03 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
CN109310748A (en) 2016-05-21 2019-02-05 传染病研究所 For treating the composition and method of secondary tuberculosis and non-tuberculous mycobacteria infection
US11801290B2 (en) 2016-09-16 2023-10-31 Access To Advanced Health Institute Vaccines comprising Mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
SI3570879T1 (en) 2017-01-20 2022-06-30 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US11123415B2 (en) 2017-08-16 2021-09-21 Ohio State Innovation Foundation Nanoparticle compositions for Salmonella vaccines
US11478541B2 (en) 2017-11-03 2022-10-25 Takeda Vaccines, Inc. Method for inactivating Zika virus and for determining the completeness of inactivation
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
AU2019256383A1 (en) 2018-04-17 2020-11-26 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP7320601B2 (en) 2018-09-11 2023-08-03 上▲海▼市公共▲衛▼生▲臨▼床中心 Broad-spectrum anti-influenza vaccine immunogen and its use
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
EP3893926A1 (en) 2018-12-12 2021-10-20 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JP7239509B6 (en) 2019-02-22 2023-03-28 ファイザー・インク Method for purifying bacterial polysaccharides
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
JP2021087420A (en) 2019-11-01 2021-06-10 ファイザー・インク Escherichia coli compositions and methods thereof
WO2021151100A1 (en) 2020-01-24 2021-07-29 Aim Immunotech Inc. Methods, compositions, and vaccines for treating a virus infection
JP2021132644A (en) 2020-02-21 2021-09-13 ファイザー・インク Purification of saccharide
KR20220143910A (en) 2020-02-23 2022-10-25 화이자 인코포레이티드 Escherichia coli composition and method thereof
CN115175924A (en) 2020-02-26 2022-10-11 港大科桥有限公司 PD-1 based vaccines against coronavirus infection
EP4185331A1 (en) * 2020-07-24 2023-05-31 The Board of Trustees of the Leland Stanford Junior University A three component vaccine for covid-19
PE20231934A1 (en) 2020-10-27 2023-12-01 Pfizer COMPOSITIONS OF ESCHERICHIA COLI AND METHODS THEREOF
AU2021373358A1 (en) 2020-11-04 2023-06-01 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
JP2023549736A (en) 2020-11-10 2023-11-29 ファイザー・インク Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
TW202245836A (en) 2021-02-19 2022-12-01 美商賽諾菲巴斯德公司 Meningococcal b recombinant vaccine
JP2024515560A (en) 2021-04-09 2024-04-10 セルデックス セラピューティクス インコーポレイテッド Antibodies to ILT4, bispecific anti-ILT4/PD-L1 antibodies, and methods of use thereof
US20240226280A1 (en) 2021-05-04 2024-07-11 King Abdullah University Of Science And Technology Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof
CA3221075A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4346892A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023079529A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Re-focusing protein booster immunization compositions and methods of use thereof
WO2023079528A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
EP4433080A1 (en) 2021-11-18 2024-09-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
CN118510548A (en) 2022-01-13 2024-08-16 辉瑞公司 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR102420201B1 (en) * 2022-01-17 2022-07-13 주식회사 유이케미칼 Eco-friendly quarantine composition with virus killing function with phospholipid envelope
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
AU2023268745A1 (en) 2022-05-11 2024-11-07 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024018061A1 (en) 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale Use of bordetella strains for the treatment of chronic obstructive pulmonary disease
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024130009A1 (en) 2022-12-14 2024-06-20 Yale University Compositions and methods of use thereof for the treatment of virally driven cancers
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024186635A2 (en) 2023-03-03 2024-09-12 Celldex Therapeutics, Inc. Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
DE3867635D1 (en) * 1987-03-13 1992-02-20 Micro Vesicular Systems LIPID VERSICLE FROM INTERFACE-ACTIVE SUBSTANCES AND STEROLS.
JPH05201877A (en) * 1992-01-30 1993-08-10 Kanebo Ltd Adjuvant composition
GB9207731D0 (en) * 1992-04-07 1992-05-27 Proteus Molecular Design Improvements in or relating to vaccines
JPH06172216A (en) * 1992-12-04 1994-06-21 Norin Suisanshiyou Kachiku Eisei Shikenjo Emulsion-like oil adjuvant
DK17093D0 (en) * 1993-02-15 1993-02-15 Lyfjathroun H F PHARMACEUTICAL PREPARATION FOR TOPIC ADMINISTRATION OF ANTIGANTS AND / OR VACCINES FOR MAMMALS THROUGH MILES
GB9320597D0 (en) * 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
CA2194761C (en) * 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides

Also Published As

Publication number Publication date
IL138000A0 (en) 2001-10-31
BR9909915A (en) 2000-12-26
HUP0101619A2 (en) 2001-08-28
KR20010042573A (en) 2001-05-25
CA2325939A1 (en) 1999-10-21
AR019026A1 (en) 2001-12-26
WO1999052549A1 (en) 1999-10-21
HUP0101619A3 (en) 2003-11-28
EP1069910A1 (en) 2001-01-24
AU746163B2 (en) 2002-04-18
JP2002511423A (en) 2002-04-16
PL354714A1 (en) 2004-02-09
AU3419799A (en) 1999-11-01
CN1296416A (en) 2001-05-23
NO20005051L (en) 2000-11-21
NO20005051D0 (en) 2000-10-06
NZ506603A (en) 2002-10-25

Similar Documents

Publication Publication Date Title
TR200002930T2 (en) Facilitating compositions
SG170127A1 (en) Vaccine compositions comprising a saponin adjuvant
PE20020968A1 (en) ZINC-FREE AND ZINC-POOR INSULIN PREPARATIONS, WITH IMPROVED STABILITY
HK1054918A1 (en) Compounds and compositions for delivering active agents
ES2140076T3 (en) VACCINES CONTAINING A SAPONIN AND A STEROL.
DE69729786D1 (en) HIGHLY CONCENTRATED, LYOPHILIZED AND LIQUID FACTOR IX FORMULATIONS
TR200002299T2 (en) Epothilon compositions.
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
AU2001262345A1 (en) Antigenic composition comprising a polycationic peptide and inosine and cytosine
BR0107869A (en) Electrogenated pharmaceutical compositions
HUP0402067A2 (en) Vaccines
AR025749A1 (en) VACCINES
BR0012429A (en) Formulations for il-11
IL154913A0 (en) Composition comprising immunogenic microparticles
DE60020570D1 (en) ROTAVIRUS VACCINE FORMULATIONS
ATE286057T1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING CLAVULANIC ACID
MXPA03003704A (en) Kahalalide f formulation.
AU2002221519A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
SE0003538D0 (en) New immunogenic complex
TR200103266T2 (en) Auxiliary combination formulations
SV1998000040A (en) PHARMACEUTICAL COMPOSITIONS REF. PU3210 / SV
ATE134294T1 (en) COMPOSITION WITH PSYLLIUM
MY128929A (en) Vaccine against hepatitis a and hepatitis b
HK1025220A1 (en) Novel saponin compositions and uses thereof
EP2116257A3 (en) Parenteral vaccine formulations and uses thereof